Home > Research > Publications & Outputs > Testing Sulforaphane for chemoprevention agains...

Electronic data

  • 2020Bellew-DunnMRes

    Final published version, 1.63 MB, PDF document

    Available under license: CC BY-NC-ND: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Text available via DOI:

View graph of relations

Testing Sulforaphane for chemoprevention against ageing and functional decline in male Drosophila models

Research output: ThesisMaster's Thesis

Published
  • Esme Bellew-Dunn
Close
Publication date2020
Number of pages77
QualificationMasters by Research
Awarding Institution
Supervisors/Advisors
Publisher
  • Lancaster University
Original languageEnglish

Abstract

Sulforaphane (SFN) has been a phytochemical of interest in targeting several
diseases. Many of these diseases are age related. Further, we can find evidence in the literature that SFN affects nearly every understood hallmark of ageing. Despite this, very little work has been carried out with SFN in the context of ageing, lifespan and functional health with age. Previous unpublished work has supported the possibility that SFN acts as a hormetic drug to improve lifespan at sub-toxic doses.

In this study, SFN was tested in the Drosophila melanogaster model organism, and its effects in lifespan, performance and biochemical hallmarks of ageing were monitored. These were assessed through three full lifespan/survival studies, a negative geotaxis assay, and a quantitative Real-Time Polymerase Chain Reaction experiment to investigate the impact of the drug on antioxidant gene expression. A High-Performance Liquid Chromatography experiment was also carried out to investigate our early findings, and test SFN absorption into fly food.

A significant improvement in lifespan was associated with SFN in only very limited conditions. White Dahomey flies reared on sugar-yeast food given 100µg/ml SFN between days 9 and 45 of their lives showed an improvement of 5.74%. Notably, Lancaster flies under identical conditions showed a significant decline (6.34%). No other significant findings were made.

These findings may indicate SFN has limited potential as an anti-ageing intervention and its effect is dramatically altered by food conditions, genetic background, and timing of dosage. However, we cannot rule out that these findings were caused by chance, and so recommend further work to verify our findings. We also hypothesise that another compound found in broccoli extract, glucoraphanin, may represent a better target for these studies, as previous work has shown low-SFN content broccoli extract to have a stronger effect than pure SFN.